Leadership BD Shift Recent appointments of Chief Business Officer Nishant Saxena and a new Board member Brent Pfeiffenberger signal renewed emphasis on business development, partnerships, and licensing strategies. This creates a favorable opening to initiate conversations on out-licensing or co-development for CRB-701 and other assets, using upcoming ASCO and investor events as engagement milestones.

ASCO BD Catalyst Corbus is actively moving data into the market through ASCO abstracts and a planned KOL event, presenting a prime window to pursue strategic collaborations, data licensing deals, or joint development arrangements with oncology partners seeking Nectin-4 ADC (CRB-701) and related oncology assets.

Obesity Platform CRB-913 provides optionality in the metabolic/obesity space, offering potential partnerships with metabolic disease companies, obesity-focused CROs, or pharma seeking co-development, licensing, or cross-indication campaigns tied to weight management and cancer care.

Dual Mechanism Opportunities The pipeline combines CRB-701, a Nectin-4 ADC, with CRB-601 targeting TGFβ activation and CRB-913 obesity program, enabling multiple collaboration angles from ADC licensing to TGFβ pathway collaborations and obesity/cancer cross-therapy partnerships.

Financial Partnerships With revenue in the tens of millions and a lean headcount, Corbus appears positioned to pursue milestone-driven partnerships and out-licensing to de-risk development and accelerate commercialization, appealing to mid-market pharmaceutical companies and CROs looking for late-stage co-development or license deals.